claudia_zurich said:

SarahChen_PharmD said: ...we don't know the long-term effects of cardiovascular risk...

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 46 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

DanielChem_CHI said:

I'm 67 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Genuinely useful, thank you. I had the facts and not the framework. Taking it to my next appointment.

claudia_zurich said:

SarahChen_PharmD said: ...we don't know the long-term effects of cardiovascular risk...

6 month update on cardiovascular risk: down 45 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

Dr.KarenChen said:

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Report rather than reply if it drifts again.